HIV-1 clade a infection and viral control: An immunological perspective on a case of underquantification

International Journal of STD and AIDS

Volumn 22, Issue 11, 2011, Pages 690-692

  Westrop, S J ^a   Jackson, A ^a   Gazzard, B ^a   Imami, N ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Clade A; HIV controller; HIV 1; Long term nonprogressor; Quantification; Viral load

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; MALE; PRIORITY JOURNAL; UNITED KINGDOM; VIRAL GENETICS; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CELL PROLIFERATION; DIAGNOSTIC ERRORS; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES; MALE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 81355153692     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009045     Document Type: Article

References (27)

1. Louwagie J, McCutchan FE, Peeters M, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. Aids 1993;7:769-780
2. UNAIDS. AIDS epidemic update, December 2007. See http://www.unaids.org/en/HIV_data/2007EpiUpdate/default.asp (last checked 18 November 2007)
3. UNAIDS. HIV in the United Kingdom: 2008 Report. See: http://data.unaids.org/pub/Report/2008/20081125_unitedkingdom_hivestimate2008_en.pdf (last accessed 18 November 2007)
4. Hart C, Schochetman G, Spira T, et al. Direct detection of HIV RNA expression in seropositive subjects. Lancet 1988;2:596-599
5. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-1179
6. Todd J, Pachl C, White R, et al. Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl 2):S35-S44
7. Murphy DG, Gonin P, Fauvel M. Reproducibility and performance of the second-generation branched-DNA assay in routine quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1999;37:812-814
8. Holguin A, de Mendoza C, Soriano V. Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes. Eur J Clin Microbiol Infect Dis 1999;18:256-259
9. Peter JB, Sevall JS. Molecular-based methods for quantifying HIV viral load. AIDS Patient Care STDS 2004;18:75-79
10. Kline NE, Schwarzwald H, Kline MW. False negative DNA polymerase chain reaction in an infant with subtype C human immunodeficiency virus 1 infection. Pediatr Infect Dis J 2002;21:885-886
11. Ananworanich J, Pancharoen C, Sirivichayakul S, et al. Undetectable plasma HIV-1 RNA with strong gag-pol specific interferon-gamma ELISPOT response in an HIV-1 clade A/E-infected child untreated with antiretroviral therapy. Asian Pac J Allergy Immunol 2004;22:165-169
12. Debyser Z, Van Wijngaerden E, Van Laethem K, et al. Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res Hum Retroviruses 1998;14:453-459
13. Stebbing J, Bower M, Mandalia S, et al. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol 2006;145:271-276
14. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996;50:825-854
15. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27:406-416
16. Tugume SB, Piwowar EM, Lutalo T, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol 1995;2:233-235
17. Imami N, Pires A, Hardy G, et al. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002;76:9011-9023
18. Burton CT, Gotch F, Imami N. Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: Concomitant assessment of perforin, IFN-g and IL-4 Secretion. J Immunol Methods 2006;308:216-230
19. Qazi N, Westrop S, Gotch F, et al. Broad HIV-1-specific T-cell responses are maintained in true long-term non-progressors. HIV Medicine 2007;8(Suppl 1):17
20. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84:1892-1899
21. Imami N, Hardy GA, Nelson MR, et al. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol 1999;118:78-86
22. Census April 2001. UK Office for National Statistics 2001. London: Census, 2001
23. Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
24. Deayton J, Groves K, Bibby D, et al. HIV-1 proviral load in elite suppressors with low or declining CD4 counts. 15th Annual Conference on Retroviruses and Opportunistic Infection. Boston, 2008
25. Kaleebu P, French N, Mahe C, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002;185:1244-1250
26. Senkaali D, Muwonge R, Morgan D, et al. The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res Hum Retroviruses 2004;20:932-937
27. Hu DJ, Vanichseni S, Mastro TD, et al. Viral load differences in early infection with two HIV-1 subtypes. Aids 2001;15:683-691